Bristol-Myers Squibb reported total revenues of $13.1 billion for the third quarter of 2026, a 7% increase compared to the prior year. Net earnings attributable to BMS remained stable at $2.2 billion for the quarter, while nine-month net earnings grew significantly from $6.0 billion in 2025 to $8.2 billion in 2026.
Bristol Myers Squibb reported third quarter 2026 revenues of $13.1 billion, a 7% increase driven by double-digit growth in its Growth Portfolio. The company raised its full-year 2026 revenue guidance to a range of $49.75 billion to $50.25 billion following strong performance from key products like Opdivo Qvantig and Reblozyl.
Term
Q3 2026
“We delivered another quarter of double-digit growth in our Growth Portfolio, which increased 12% and reflects the continued momentum across our diversified portfolio. The approval of Zenbexus, the first-in-class CELMoD, brings a new class of treatment to market for patients with multiple myeloma and is one of several recent pipeline milestones. As we look forward to additional late-stage data in the near term, we remain focused on executing with discipline, investing where we see the greatest opportunity and strengthening the foundation for sustainable growth.”
Christopher Boerner, Ph.D., board chair and chief executive officer, Bristol Myers Squibb